The effectiveness of two large shelves removes the last procedural barrier to a capital raise. Given the company's cash runway (likely <3 quarters at current burn) and the cross-filing amplifier signal, monitor for a takedown announcement (via 424B5 or 8-K) within the next 30-60 days. Any offering could be highly dilutive given the shelf-to-market-cap ratio.
Price Chart
How similar events traded
Executive Summary
Two shelf registration statements (File Nos. 333-286226 and 333-256611) for Forte Biosciences became effective on September 1, 2026. These shelves, originally filed in June 2026, each register up to $500M in securities, enabling the company to raise capital at any time. With a $1.6B market cap, the combined $1B shelf capacity represents ~63% of current market value, creating a persistent dilution overhang for a clinical-stage biopharma with no revenue and accelerating cash burn ($22.1M net loss in Q1 2026). The cross-filing actuarial verdict confirms this is an amplifier, the shelf effectiveness materially increases near-term equity issuance risk.
Key Facts
- Two shelf registration statements (333-286226 and 333-256611) became effective on September 1, 2026.
- Each shelf registers up to $500M in securities (common, preferred, debt, warrants, etc.), for a combined $1B capacity.
- Forte Biosciences is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026.
- The $1B shelf capacity represents ~63% of the current $1.6B market cap, signaling substantial potential dilution.
- The cross-filing actuarial verdict confirms this combo (IPO-context + shelf-context) is an amplifier, supporting an elevated impact score.
Financial Impact
Combined $1B shelf capacity vs $1.6B market cap (~63% potential dilution); company had $58.2M cash and $22.1M quarterly net loss as of Q1 2026
Risk Factors
- Imminent equity offering with significant dilution (~63% of market cap in shelf capacity)
- Accelerating cash burn ($22.1M quarterly loss) with limited cash runway ($58.2M)
- Clinical-stage biotech with no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (FBRX), Batch item 1 | 9999999995-26-002848 |
| Document: 9999999995-26-002848-index.html | 9999999995-26-002844 |
| Document: 9999999995-26-002848.txt | 9999999995-26-002848 |
| EFFECT Filing (FBRX), Batch item 4 | 9999999995-26-002844 |
| Document: 9999999995-26-002844-index.html | 9999999995-26-002848 |
| Document: 9999999995-26-002844.txt | 9999999995-26-002848 |
Track record
15 reports on FBRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Viewing Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers